Boothbay Fund Management’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.6M Sell
953,126
-129,485
-12% -$2.48M 0.23% 82
2026
Q2
$19.7M Sell
1,082,611
-30,192
-3% -$448K 0.26% 60
2026
Q1
$15.8M Sell
1,112,803
-124,240
-10% -$1.6M 0.21% 61
2025
Q4
$12.8M Buy
+1,237,043
New +$11.2M 0.19% 97
2021
Q3
– Sell
-39,113
Closed -$1.01M – 1919
2021
Q2
$1.01M Buy
+39,113
New +$1.2M 0.03% 682

Other funds holding CGEM

Boothbay Fund Management's CGEM Position: Q3 2026 in Review

Boothbay Fund Management reduced its Cullinan Therapeutics (CGEM) stake by 12% in Q3 2026, selling an estimated $2.48M and leaving 953,126 shares worth $14.6M. The position accounts for 0.23% of the portfolio, ranked #82.

Boothbay Fund Management first reported a position in CGEM in Q2 2021 and has held it in 5 quarters since. The position peaked at $19.7M in Q2 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Boothbay Fund Management held 953,126 shares of Cullinan Therapeutics worth $14.6M as of Q3 2026.
  • Boothbay Fund Management sold 129,485 Cullinan Therapeutics shares in Q3 2026, an estimated $2.48M.
  • Cullinan Therapeutics made up 0.23% of Boothbay Fund Management's portfolio in Q3 2026, its #82 holding.
  • Boothbay Fund Management first reported a position in Cullinan Therapeutics in Q2 2021 and has held it in 5 quarters since.
  • Boothbay Fund Management's Cullinan Therapeutics position peaked at $19.7M in Q2 2026.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.